+

WO2002072067A3 - Formulation aerosol pharmaceutique - Google Patents

Formulation aerosol pharmaceutique Download PDF

Info

Publication number
WO2002072067A3
WO2002072067A3 PCT/GB2002/001096 GB0201096W WO02072067A3 WO 2002072067 A3 WO2002072067 A3 WO 2002072067A3 GB 0201096 W GB0201096 W GB 0201096W WO 02072067 A3 WO02072067 A3 WO 02072067A3
Authority
WO
WIPO (PCT)
Prior art keywords
aerosol formulation
pharmaceutical aerosol
pharmaceutical
hydrofluoroalkane
hfa
Prior art date
Application number
PCT/GB2002/001096
Other languages
English (en)
Other versions
WO2002072067A2 (fr
Inventor
Paul Johnson
Original Assignee
Glaxo Group Ltd
Paul Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0106018A external-priority patent/GB0106018D0/en
Priority claimed from GB0128335A external-priority patent/GB0128335D0/en
Application filed by Glaxo Group Ltd, Paul Johnson filed Critical Glaxo Group Ltd
Priority to AU2002238748A priority Critical patent/AU2002238748A1/en
Publication of WO2002072067A2 publication Critical patent/WO2002072067A2/fr
Publication of WO2002072067A3 publication Critical patent/WO2002072067A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une formulation aérosol pharmaceutique comportant un propulseur hydrofluoroalcane (HFA) dans lequel est dissous (2R,3R,4S,5R)-2-[6-amino-2-(1S-hydroxyméthyl-2-phényléthylamino)-purine-9-yl]-5-(2-éthyl-2H-tétrazol-5-yl)-tétrahydrofurane-3,4-diol ou un sel ou solvate de ce dernier.
PCT/GB2002/001096 2001-03-12 2002-03-11 Formulation aerosol pharmaceutique WO2002072067A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002238748A AU2002238748A1 (en) 2001-03-12 2002-03-11 Pharmaceutical aerosol formulation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0106018.5 2001-03-12
GB0106018A GB0106018D0 (en) 2001-03-12 2001-03-12 Pharmaceutical aerosol formulation
GB0128335.7 2001-11-27
GB0128335A GB0128335D0 (en) 2001-11-27 2001-11-27 Pharmaceutical aerosol formulation

Publications (2)

Publication Number Publication Date
WO2002072067A2 WO2002072067A2 (fr) 2002-09-19
WO2002072067A3 true WO2002072067A3 (fr) 2004-02-19

Family

ID=26245812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001096 WO2002072067A2 (fr) 2001-03-12 2002-03-11 Formulation aerosol pharmaceutique

Country Status (2)

Country Link
AU (1) AU2002238748A1 (fr)
WO (1) WO2002072067A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024420A1 (fr) * 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Compositions pharmaceutiques et leurs dispositifs d'administration
WO1998028319A1 (fr) * 1996-12-24 1998-07-02 Glaxo Group Limited Derives de 2-(purine-9-yl)-tetrahydrofuran-3,4-diol
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
WO2000023457A1 (fr) * 1998-10-16 2000-04-27 Pfizer Limited Derives d'adenine
WO2000077018A2 (fr) * 1999-06-15 2000-12-21 Pfizer Limited Derives de purine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024420A1 (fr) * 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Compositions pharmaceutiques et leurs dispositifs d'administration
WO1998028319A1 (fr) * 1996-12-24 1998-07-02 Glaxo Group Limited Derives de 2-(purine-9-yl)-tetrahydrofuran-3,4-diol
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
WO2000023457A1 (fr) * 1998-10-16 2000-04-27 Pfizer Limited Derives d'adenine
WO2000077018A2 (fr) * 1999-06-15 2000-12-21 Pfizer Limited Derives de purine

Also Published As

Publication number Publication date
WO2002072067A2 (fr) 2002-09-19
AU2002238748A1 (en) 2002-09-24

Similar Documents

Publication Publication Date Title
AU2002364730A1 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
IL168266A (en) Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments
PL398295A1 (pl) Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania
PT1401841E (pt) Derivados substituidos de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno como medicamentos para o tratamento da dor
HUP0401109A3 (en) Nociceptin analogs, their use and pharmaceutical compositions containing them
PT1465535E (pt) Microprojecções que perfuram a pele tendo controlo de profundidade de perfuração
HK1053163A1 (en) Variable speed drive chiller system.
HUP0401293A3 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
NO20040678L (no) Aminoalkyl-substituert aromatiske bicykliske forbindelser, fremgangsmate for deres fremstilling og deres anvendelse som legemidler.
IL159715A0 (en) Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
HUP0402063A3 (en) Indole-2-carboxamides process for producing them, pharmaceutical compositions containing them and use thereof
WO2005084181A3 (fr) Flacon accessible sans aiguille
ITMI20021893A1 (it) Dispositivo di sicurezza per vani interni praticabili,
WO2002092006A3 (fr) Composes a base d'acides nucleiques et procedes d'utilisation associes
NO20042158L (no) Substituert 4-fenyl-tetrahydroisokinoliner, fremgangsmate for fremstilling derav, anvendelse derav som medikamenter, i tillegg til medikamenter inneholdende samme
AP2004002968A0 (en) Single dose azithromycin for treating respiratory infections.
DE60042585D1 (de) 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
WO2002072067A3 (fr) Formulation aerosol pharmaceutique
WO2003025139A3 (fr) Administration d'acides nucleiques, d'analogues et de derives de ceux-ci induite par cobalamine
MXPA03006648A (es) Compuestos antitombroticos, su preparacion y su utilizacion como medicamentos.
IL173918A0 (en) Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicaments comprising the same
ZA200409095B (en) Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same.
AU2002349751A1 (en) Shock absorption type steering column device
HUP0302521A3 (en) Neurotrophic tacrolimus analogs, pharmaceutical compositions containing them and their use
AU2002238673A1 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载